Ekaterina Friebel

Ekaterina Friebel

Auto-generated profile, based on publicly available information

Ekaterina Friebel

Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Nature
Verified
Journal Article
Open access
PDF file
DPDominik Pfister
Dominik Pfister
NNNicolás Gonzalo Núñez
Nicolás Gonzalo Núñez
RPRoser Pinyol
Roser Pinyol
OGOlivier Govaere
Olivier Govaere
MPMatthias Pinter
Matthias Pinter
MHMathias Heikenwälder
Mathias Heikenwälder
Hepatocellular carcinoma (HCC) can have viral or non-viral causes1–5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH–HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+T cells or TNF neutralization, suggesting that CD8+T cells help to induce NASH–HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH–HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

16 February 2024 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
JRJosefine Radke
Josefine Radke
JMJenny Meinhardt
Jenny Meinhardt
TATom Aschman
Tom Aschman
RCRobert Lorenz Chua
Robert Lorenz Chua
VFVadim Farztdinov
Vadim Farztdinov
HRHelena Radbruch
Helena Radbruch

25 September 2023 in Nature Neuroscience
Verified
Journal Article
Open access
PDF file
MAMyrto Andreadou
Myrto Andreadou
FIFlorian Ingelfinger
Florian Ingelfinger
DFDonatella De Feo
Donatella De Feo
TCTeresa L. M. Cramer
Teresa L. M. Cramer
STSelma Tuzlak
Selma Tuzlak
BBBurkhard Becher
Burkhard Becher
Interleukin-12 (IL-12) is a potent driver of type 1 immunity. Paradoxically, in autoimmune conditions, including of the CNS, IL-12 reduces inflammation. The underlying mechanism behind these opposing properties and the involved cellular players remain elusive. Here we map IL-12 receptor (IL-12R) expression to NK and T cells as well as neurons and oligodendrocytes. Conditionally ablating the IL-12R across these cell types in adult mice and assessing their susceptibility to experimental autoimmune encephalomyelitis revealed that the neuroprotective role of IL-12 is mediated by neuroectoderm-derived cells, specifically neurons, and not immune cells. In human brain tissue from donors with multiple sclerosis, we observe an IL-12R distribution comparable to mice, suggesting similar mechanisms in mice and humans. Combining flow cytometry, bulk and single-nucleus RNA sequencing, we reveal an IL-12-induced neuroprotective tissue adaption preventing early neurodegeneration and sustaining trophic factor release during neuroinflammation, thereby maintaining CNS integrity in mice.

16 December 2021 in Nature Aging
Verified
Journal Article
Open access
PDF file
SKSinduya Krishnarajah
Sinduya Krishnarajah
FIFlorian Ingelfinger
Florian Ingelfinger
EFEkaterina Friebel
Ekaterina Friebel
DCDilay Cansever
Dilay Cansever
AAAna Amorim
Ana Amorim
BBBurkhard Becher
Burkhard Becher
Aging exerts profound and paradoxical effects on the immune system, at once impairing proliferation, cytotoxicity and phagocytosis, and inducing chronic inflammation. Previous studies have focused on individual tissues or cell types, while a comprehensive multisystem study of tissue-resident and circulating immune populations during aging is lacking. Here we reveal an atlas of age-related changes in the abundance and phenotype of immune cell populations across 12 mouse tissues. Using cytometry-based high parametric analysis of 37 mass-cytometry and 55 spectral flow-cytometry parameters, mapping samples from young and aged animals revealed conserved and tissue-type-specific patterns of both immune atrophy and expansion. We uncovered clear phenotypic changes in both lymphoid and myeloid lineages in aged mice, and in particular a contraction in natural killer cells and plasmacytoid dendritic cells. These changes correlated with a skewing towards myelopoiesis at the expense of early lymphocyte genesis in aged mice. Taken together, this atlas represents a comprehensive, systematic and thorough resource of the age-dependent alterations of the mammalian immune system in lymphoid, barrier and solid tissues.

13 March 2025 in Nature Aging
Verified
Journal Article
Open access
PDF file
SSShirin Schneeberger
Shirin Schneeberger
SKSeung Joon Kim
Seung Joon Kim
MGMaria N. Geesdorf
Maria N. Geesdorf
EFEkaterina Friebel
Ekaterina Friebel
PEPascale Eede
Pascale Eede
FHFrank L. Heppner
Frank L. Heppner
Neuroinflammation including interleukin (IL)-12/IL-23-signaling is central to Alzheimer’s disease (AD) pathology. Inhibition of p40, a subunit of IL-12/IL-23, attenuates pathology in AD-like mice; however, its signaling mechanism and expression pattern remained elusive. Here we show that IL-12 receptors are predominantly expressed in neurons and oligodendrocytes in AD-like APPPS1 mice and in patients with AD, whereas IL-23 receptor transcripts are barely detectable. Consistently, deletion of the IL-12 receptor in neuroectodermal cells ameliorated AD pathology in APPPS1 mice, whereas removal of IL-23 receptors had no effect. Genetic ablation of IL-12 signaling alone reverted the loss of mature oligodendrocytes, restored myelin homeostasis, rescued the amyloid-β-dependent reduction of parvalbumin-positive interneurons and restored phagocytosis-related changes in microglia of APPPS1 mice. Furthermore, IL-12 protein expression was increased in human AD brains compared to healthy age-matched controls, and human oligodendrocyte-like cells responded profoundly to IL-12 stimulation. We conclude that oligodendroglial and neuronal IL-12 signaling, but not IL-23 signaling, are key in orchestrating AD-related neuroimmune crosstalk and that IL-12 represents an attractive therapeutic target in AD.

26 November 2021 in Science Immunology
Verified
Journal Article
Closed access
CHClaudia Haftmann
Claudia Haftmann
PZPascale Zwicky
Pascale Zwicky
FIFlorian Ingelfinger
Florian Ingelfinger
FMFlorian Mair
Florian Mair
SFStefan Floess
Stefan Floess
BBBurkhard Becher
Burkhard Becher
Thymic education of regulatory T cells is more important than negative selection in the prevention of autoimmunity.